CytomX Therapeutics, Inc. (CTMX) Investor Relations Documents

CytomX Therapeutics, Inc. (CTMX) investor relations documents from the company's IR site: 1 presentation, 35 press releases; latest deck 2026-08-07. Read in-app with summaries. First-party data.

CytomX Therapeutics Corporate Presentation – August 2026: CytomX Therapeutics reports Q2 2026 progress on its PROBODY platform, targeting a registrational study for lead ADC Varseta-M in late-line colorectal cancer by 1H 2027.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-07PresentationCytomX Therapeutics Corporate Presentation – August 2026
2026-08-06Press releasePDF Version
2026-08-06Press releaseCytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update
2026-08-03Press releasePDF Version
2026-08-03Press releaseCytomX Therapeutics Appoints Alejandra Carvajal as Chief Legal Officer
2026-07-30Press releasePDF Version
2026-07-30Press releaseCytomX Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026
2026-07-27Press releasePDF Version
2026-07-27Press releaseCytomX Therapeutics Announces Appointment of Charles Fuchs, M.D., M.P.H., to the Board of Directors
2026-06-03Press releasePDF Version
2026-06-03Press releaseCytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific The
2026-05-21Press releasePDF Version
2026-05-21Press releaseCytomX Therapeutics to Present at Upcoming June Investor Conferences
2026-05-18Press releasePDF Version
2026-05-18Press releaseCytomX Therapeutics Appoints Mamata Gokhale, Ph.D., RAC, as Senior Vice President of Regulatory Affairs
2026-05-07Press releasePDF Version
2026-05-07Press releaseCytomX Therapeutics Announces Q1 2026 Financial Results and Provides Business Update
2026-04-30Press releasePDF Version
2026-04-30Press releaseCytomX Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026
2026-03-17Press releasePDF Version
2026-03-17Press releaseCytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants
Press releaseCytomX Therapeutics Announces 2025 Financial Results and Provides Business Update
2026-03-16Press releasePDF Version
2026-03-16Press releasePDF Version
2026-03-16Press releasePDF Version
2026-03-16Press releaseCytomX Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
2026-03-16Press releaseCytomX’s Varsetatug Masetecan (EpCAM PROBODY® ADC) Continues to Demonstrate Positive Data Supporting Potential as a New
2026-03-04Press releasePDF Version
2026-03-04Press releaseCytomX Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on March 16, 2026
2026-02-04Press releasePDF Version
2026-02-04Press releaseCytomX Therapeutics to Present at Upcoming February Conferences
2026-01-08Press releasePDF Version
2026-01-08Press releaseCytomX Therapeutics Announces Business Update and Company Milestones for 2026
DocumentCytomX Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update
Press releaseCytomX Therapeutics to Report Third Quarter 2025 Financial Results on November 6, 2025
DocumentCytomX Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update
Press releaseCytomX Therapeutics to Report Second Quarter 2025 Financial Results on August 7, 2025
DocumentCytomX Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update
Press releaseCytomX Therapeutics to Report First Quarter 2025 Financial Results on May 12, 2025

CTMX overview · CTMX earnings · CTMX financials · CTMX KPIs · CTMX documents · CTMX ownership · CTMX peers

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.